Copenhagen Center for Glycomics Collaborates with Desktop Genetics to Analyze their Novel CRISPR Assay
News Dec 19, 2017
The project is designed to provide a deeper understanding of a novel method of identifying nuclease-generated mutations developed by the lab of Dr. Eric Paul Bennett. The method is currently used by CCG and its spin-out company, Glycodisplay Aps. The improvements to this tool will be a driver for broader use in academia and industry.
The method developed by Dr. Bennett, called Indel Detection by Amplicon Analysis (IDAA), significantly reduces the workload of cell line editing by facilitating the initial screening of newly generated nuclease reagents, as well as the subsequent generation of edited cell pools or clonal cell lines. It reduces the number of clones necessary to create a stable cell line and increases the ease with which they are screened. Desktop Genetics will analyze CRISPR indel formation using their machine learning expertise. Their team will be working with CCG to analyze a dataset of 800 guides designed on the DESKGEN Cloud platform to explore the capabilities of IDAA.
Dr. Bennett said, “We realized that an in-depth analysis of the experimentally validated, unbiased and well defined-indel profiles generated by 800 unique Cas9 guides could contribute to improving the predictive value of guide RNA design algorithms. Therefore, Desktop Genetics, with its leading position in the field of genome editing bioinformatics, was chosen as a partner to undertake this extensive analytical task.”
Dr. Leigh Brody added, “This co-investigation will enable researchers to extract much more information from the IDAA assay by combining Eric’s and our teams’ expertise to deeply analyze these interesting datasets. This will provide a better understanding of CRISPR activity and, in turn, serve our broader goal of offering a comprehensive solution for genome editing analysis.”
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE